Login to Your Account

Clinic Roundup

Tuesday, February 28, 2012
• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said results from a 30-patient Phase Ib study demonstrated that its GVAX pancreas cancer vaccine increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma by more than 60 percent, from 3.3 months when treated with Yervoy (ipilimumab, Bristol-Myers Squibb Co.) to 5.5 months on ipilimumab plus the GVAX pancreas vaccine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription